Despite an apparent return to dealmaking grandeur in 2023, the biopharma industry’s appetite for large-scale mergers and acquisitions was notably more muted over the past 12 months. And, while 2025 may not see a return to major outlays, plenty more transactions are likely to transpire as large pharmas look to deploy their cash, multiple analyst groups contend. Taking a closer look at the top transactions of 2024, Novo Holdings’ $16.5 billion buyout of CDMO stalwart Catalent—which closed in late December—marked the year’s biggest deal by value.
Read the full article: The Top 10 Biopharma M&A Deals of 2024 //
Source: https://www.fiercepharma.com/pharma/top-10-biopharma-ma-deals-2024